Natalizumab Terminated Phase 2 Trials for Relapsing Multiple Sclerosis (RMS) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02142192Natalizumab Subcutaneous Immunogenicity and Safety Study